

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6864434

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
NEVAKAR INC.	07/30/2021

**RECEIVING PARTY DATA**

<b>Name:</b>	NEVAKAR INJECTABLES INC.
<b>Street Address:</b>	1019 US HIGHWAY 202-206
<b>City:</b>	BRIDGEWATER
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08807

**PROPERTY NUMBERS Total: 54**

Property Type	Number
Application Number:	15292810
PCT Number:	US1815779
Application Number:	62452220
Patent Number:	10226436
Patent Number:	10159657
Patent Number:	10420735
Patent Number:	10646458
Patent Number:	10471026
Patent Number:	10568850
Application Number:	16839450
Application Number:	62492771
Application Number:	62567384
PCT Number:	US1864319
Application Number:	62595938
PCT Number:	US1917524
Application Number:	62642326
Application Number:	16272815
Application Number:	16836152
Application Number:	16836483
Application Number:	16836581

PATENT

Property Type	Number
Application Number:	16909340
Application Number:	17142744
PCT Number:	US1923462
Application Number:	62647303
Application Number:	16360995
Application Number:	16788831
Application Number:	16821689
Application Number:	16821785
PCT Number:	US1853195
Application Number:	62564699
Application Number:	62812163
PCT Number:	US2034359
Application Number:	62853597
Application Number:	62857188
PCT Number:	US2017875
Application Number:	16749378
Application Number:	17096822
PCT Number:	US2114404
Application Number:	62964457
Application Number:	17154516
PCT Number:	US2133008
Application Number:	63026654
Application Number:	17323781
Application Number:	63068516
PCT Number:	US2143061
PCT Number:	US2118605
Application Number:	62978624
Application Number:	17179078
PCT Number:	US2118368
Application Number:	62978128
Application Number:	17177797
Application Number:	62978648
PCT Number:	US2138419
Application Number:	63043372

**CORRESPONDENCE DATA**

Fax Number: (949)679-0461

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**PATENT**

**REEL: 057183 FRAME: 0826**

**Phone:** 949-679-0052  
**Email:** dmoroz@umbergzipser.com  
**Correspondent Name:** UMBERG ZIPSER LLP  
**Address Line 1:** 1920 MAIN STREET  
**Address Line 2:** SUITE 750  
**Address Line 4:** IRVINE, CALIFORNIA 92614

**ATTORNEY DOCKET NUMBER:** 104283.0000

**NAME OF SUBMITTER:** DANIELLE MOROZ

**SIGNATURE:** /Danielle Moroz/

**DATE SIGNED:** 08/13/2021

**Total Attachments: 5**

source=Assignment\_Nevakar Inc to Nevakar Injectables-Signed#page1.tif

source=Assignment\_Nevakar Inc to Nevakar Injectables-Signed#page2.tif

source=Assignment\_Nevakar Inc to Nevakar Injectables-Signed#page3.tif

source=Assignment\_Nevakar Inc to Nevakar Injectables-Signed#page4.tif

source=Assignment\_Nevakar Inc to Nevakar Injectables-Signed#page5.tif

ASSIGNMENT AGREEMENT

WHEREAS, the undersigned, **NEVAKAR INC.**, a company located at **1019 US Highway 202-206, Bridgewater, NJ 08807, United States** (referred to hereinafter as "ASSIGNOR") has obtained by way of assignment certain and useful inventions for which applications for United States Letters Patent were filed as listed in **SCHEDULE A**, which together with related experimental data, trade secret, and other know-how are referred to hereinafter as the **INVENTIONS**;

WHEREAS, **NEVAKAR INJECTABLES INC.** a company, having its principal place of business at **1019 US Highway 202-206, Bridgewater, NJ 08807, United States** (referred to hereinafter as "ASSIGNEE"), is desirous of acquiring all entire right, title and interest in, to and under said **INVENTIONS**, and in, to and under Letters Patent or similar legal protection to be, or having been, obtained therefor in the United States of America, its territorial possessions and in any and all countries foreign thereto.

WHEREAS, **ASSIGNOR** hereby authorizes and request **ASSIGNEE's** attorneys of record to insert or correct the serial number(s), filing date(s), or other identification of the **INVENTION** when known and as needed.

**NOW, THEREFORE**, for good and valuable consideration, the receipt of which is hereby acknowledged, **ASSIGNOR** hereby sells, assigns, transfers and sets over unto the **ASSIGNEE**, its successors, and assign the entire title, right and interest in and to the **INVENTION**, and to all Letters Patent or similar legal protection arising therefrom, not only in the United States and its territorial possessions, but in all countries foreign thereto to be obtained for said **INVENTION** by said application or any continuation, continuation-in-part, divisional, renewal, substitute, reissue or reexamination thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted, including all priority rights under any International Conventions, and including all rights to sue for past, present or future infringement.

**ASSIGNOR** hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

**ASSIGNOR** further covenants that **ASSIGNEE** will, upon its request, be provided promptly with all pertinent facts and documents relating to said **INVENTION**, including the patent application listed above, and any Letters Patent and legal equivalents in foreign countries issuing therefrom as may be known and accessible to **ASSIGNOR**, and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to **ASSIGNEE** or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said invention and said Letters Patent and said equivalents thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof. **ASSIGNOR** hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said **Invention** to **ASSIGNEE**.

ASSIGNOR and ASSIGNEE each covenants to perform all acts and execute and deliver all documents as may be necessary or appropriate to carry out the intent and purposes of this assignment.

This ASSIGNMENT embodies the entire understanding of ASSIGNOR and ASSIGNEE and supersedes and replaces any and all pre-existing assignments or understandings between ASSIGNOR and ASSIGNEE. No amendment or modification of this assignment shall be valid or binding upon ASSIGNOR or ASSIGNEE unless made in writing and signed on behalf of each of ASSIGNOR and ASSIGNEE by their respective duly authorized representative.


ASSIGNOR acknowledges that ASSIGNEE may appoint any attorney or practitioner of ASSIGNEE'S choice to prosecute any application or other legal proceeding involving said invention and ASSIGNOR further acknowledges that any attorney or practitioner so appointed by ASSIGNEE does not represent ASSIGNOR and that such appointment by ASSIGNEE does not create any attorney-client relationship between ASSIGNOR and any attorney or practitioner appointed by ASSIGNEE, in this or in any PCT or other family applications.

This ASSIGNMENT may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.


This ASSIGNMENT shall be governed by and construed in accordance with the law of the state of California and ASSIGNOR and ASSIGNEE agree to submit to the exclusive jurisdiction of the courts of the state of California.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed, in duplicate, by their duly authorized officers or representatives.

ASSIGNOR  
NEVAKAR INC.

By: 

ASSIGNEE  
NEVAKAR INJECTABLES INC.

By: 

Date: 7/30/20

Date: 7/30/20

**SCHEDULE A**

<b>UZ Ref.</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Title</b>	<b>Patent No.</b>	<b>Issue Date</b>
102843.0001US	15/292,810	October 13, 2016	FULVESTRANT COMPOSITIONS		
102843.0002PCT	PCT/US18/15779	January 29, 2018	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR		
102843.0002PRO	62/452,220	January 30, 2017	NOREPINEPHRINE COMPOSITIONS AND CONTAINERS		
102843.0002US	15/883,798	January 30, 2018	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,226,436	March 12, 2019
102843.0002US2	15/949,736	April 10, 2018	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,159,657	December 25, 2018
102843.0002US3	16/163,480	October 17, 2018	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,420,735	September 24, 2019
102843.0002US4	16/239,465	January 3, 2019	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,646,458	May 12, 2020
102843.0002US5	16/163,476	October 17, 2018	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,471,026	November 12, 2019
102843.0002US6	16/239,461	January 3, 2019	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR	10,568,850	February 25, 2020
102843.0002US7	16/839,450	April 3, 2020	NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR		
102843.0003PRO	62/492,771	May 1, 2017	DAPTOMYCIN FORMULATIONS		
102843.0004PRO	62/567,384	October 3, 2017	ACETAMINOPHEN PREGABALIN COMBINATIONS AND METHODS OF TREATING PAIN		
102843.0005PCT	PCT/US18/64319	December 6, 2018	CONCENTRATED FULVESTRANT COMPOSITIONS		
102843.0005PRO	62/595,938	December 7, 2017	CONCENTRATED FULVESTRANT COMPOSITIONS		
102843.0005US	16/769,204	June 2, 2020	CONCENTRATED FULVESTRANT COMPOSITIONS		
102843.0007PCT	PCT/US19/17524	February 11, 2019	PREFILLED SYRINGE, COMPOSITIONS AND METHODS		
102843.0007PRO	62/642,326	March 13, 2018	PREFILLED SYRINGE, COMPOSITIONS AND METHODS		
102843.0007US	16/272,815	February 11, 2019	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS	10,682,308	June 16, 2020
102843.0007US2	16/836,152	March 31, 2020	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS	10,722,453	July 28, 2020
102843.0007US3	16/836,483	March 31, 2020	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS	10,722,454	July 28, 2020

**SCHEDULE A**

102843.0007US4	16/836,581	March 31, 2020	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS	10,722,455	July 28, 2020
102843.0007USS	16/909,340	June 23, 2020	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS		
102843.0007US6	17/142,744	January 6, 2021	SUCCINYLCHOLINE PREFILLED SYRINGE, COMPOSITIONS AND METHODS		
102843.0008PCT	PCT/US19/23462	March 21, 2019	EPINEPHRINE COMPOSITIONS AND CONTAINERS		
102843.0008PRO	62/647,303	March 23, 2018	EPINEPHRINE COMPOSITIONS AND CONTAINERS		
102843.0008US	16/360,995	March 21, 2019	EPINEPHRINE COMPOSITIONS AND CONTAINERS	10,653,646	May 19, 2020
102843.0008US2	16/788,831	February 12, 2020	EPINEPHRINE COMPOSITIONS AND CONTAINERS	11,071,719	July 27, 2021
102843.0008US3	16/821,689	March 17, 2020	EPINEPHRINE COMPOSITIONS AND CONTAINERS	11,083,698	August 10, 2021
102843.0008US4	16/821,785	March 17, 2020	EPINEPHRINE COMPOSITIONS AND CONTAINERS		
102843.0010PCT	PCT/US18/53195	September 27, 2018	FIXED DOSE COMBINATION FORMULATIONS FOR TREATING PAIN		
102843.0010PRO	62/564,699	September 28, 2017	FIXED DOSE COMBINATION FORMULATIONS FOR TREATING PAIN		
102843.0010US	16/644,022	March 3, 2020	FIXED DOSE COMBINATION FORMULATIONS FOR TREATING PAIN		
102843.0012PRO	62/812,163	February 28, 2019	VASOPRESSIN COMPOSITIONS AND METHODS THEREFOR		
102843.0013PCT	PCT/US20/34359	May 22, 2020	VANCOMYCIN LIPOSOME COMPOSITIONS AND METHODS		
102843.0013PRO	62/853,597	May 28, 2019	VANCOMYCIN LIPOSOME COMPOSITIONS AND METHODS		
102843.0014PRO	62/857,188	June 4, 2019	FORMULATIONS OF BACLOFEN		
102843.0015PCT	PCT/US20/17875	February 12, 2020	EPHEDRINE COMPOSITIONS AND METHODS		
102843.0015US	16/749,378	January 22, 2020	EPHEDRINE COMPOSITIONS AND METHODS	10,869,845	December 22, 2020
102843.0015US2	17/096,822	November 12, 2020	EPHEDRINE COMPOSITIONS AND METHODS		

**SCHEDULE A**

102843.0016PCT	PCT/US21/14404	January 21, 2021	PHENYLEPHRINE HYDROCHLORIDE COMPOSITIONS AND CONTAINERS		
102843.0016PRO	62/964,457	January 22, 2020	PHENYLEPHRINE HYDROCHLORIDE COMPOSITIONS AND CONTAINERS		
102843.0016US	17/154,516	January 21, 2021	PHENYLEPHRINE HYDROCHLORIDE COMPOSITIONS AND CONTAINERS		
102843.0017PCT	PCT/US21/33008	May 18, 2021	LOW-DOSE CARBACHOL COMPOSITIONS AND METHODS FOR TREATMENT OF NIGHT VISION DISTURBANCE		
102843.0017PRO	63/026,654	May 18, 2020	LOW-DOSE CARBACHOL COMPOSITIONS AND METHODS FOR TREATMENT OF NIGHT VISION DISTURBANCE		
102843.0017US	17/323,781	May 18, 2021	LOW-DOSE CARBACHOL COMPOSITIONS AND METHODS FOR TREATMENT OF NIGHT VISION DISTURBANCE		
102843.0018PRO	63/068,516	August 21, 2020	LOW-DOSE OPHTHALMIC COMPOSITIONS AND METHODS		
102843.0019PCT	PCT/US21/18605	February 18, 2021	ISOPROTERENOL COMPOSITIONS AND METHODS		
102843.0019PRO	62/978,624	February 19, 2020	ISOPROTERENOL COMPOSITIONS AND METHODS		
102843.0019US	17/179,078	February 18, 2021	ISOPROTERENOL COMPOSITIONS AND METHODS		
102843.0020PCT	PCT/US21/18368	February 17, 2021	N-ACETYLCYSTEINE COMPOSITIONS AND METHODS		
102843.0020PRO	62/978,128	February 18, 2020	N-ACETYLCYSTEINE COMPOSITIONS AND METHODS		
102843.0020US	17/177,797	February 17, 2021	N-ACETYLCYSTEINE COMPOSITIONS AND METHODS		
102843.0021PRO	62/978,648	February 19, 2020	CISATRACURIUM BESYLATE COMPOSITIONS AND CONTAINERS THEREFOR		
102843.0023PCT	PCT/US21/38419	June 22, 2021	METHODS FOR REDUCING CATECHOLAMINE-FORMALDEHYDE ADDUCTS		
102843.0023PRO	63/043,372	June 24, 2020	METHODS FOR REDUCING CATECHOLAMINE-FORMALDEHYDE ADDUCTS		

**PATENT**

**REEL: 057183 FRAME: 0832**

**RECORDED: 08/13/2021**